Press Release

Illumina to Announce Second Quarter 2014 Financial Results on Wednesday, July 23, 2014

SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2014-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2014 following the close of market on Wednesday, July 23, 2014.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jay Flatley, Chief Executive Officer, Francis deSouza, President, and Marc Stapley, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Wednesday, July 23, 2014. Interested parties may listen to the call by dialing 888-679-8034 (passcode: 60693837), or if outside North America by dialing +1-617-213-4847 (passcode: 60693837). Individuals may access the live teleconference in the Investor Relations section of Illumina’s web site under the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 6:00 pm Pacific Time (9:00 pm Eastern Time) on July 23, 2014 through July 30, 2014 by dialing 888-286-8010 (passcode: 85586770), or if outside North America by dialing +1-617-801-6888 (passcode: 85586770).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its applications, paving the way for molecular medicine and ultimately transforming healthcare.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858.255.5243
rchambers@illumina.com
or
Media:
Eric Endicott
858.882.6822
pr@illumina.com

Recent Articles

Trailblazing study shows early CGP leads to better precision treatments
Trailblazing study shows early CGP leads to better precision treatments
How two systems integration scientists ensure a smooth workflow on MiSeq i100
How two systems integration scientists ensure a smooth workflow on MiSeq i100
Single-cell RNA analysis finds possible genetic drivers of bone cancer
Single-cell RNA analysis finds possible genetic drivers of bone cancer